17 March 2025
Full Year results for the 12 months ended 31 December 2024 Resilient performance in 2024 with strong foundations in place to drive medium-term outperformance…
Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial Trial continues as planned…
Imfinzi approved in the EU as first and only immunotherapy for limited-stage small cell lung cancer Approval based on ADRIATIC Phase III trial results which…
AstraZeneca to acquire EsoBiotec to advance cell therapy ambition Acquisition includes world-leading in vivo delivery platform with potential to transform cell therapy AstraZeneca has…
13 March 2025
Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 13 March 2025 – Euronext announces that it has entered into a definitive agreement with Visma to…
FULLER, SMITH & TURNER P.L.C. Business Update Fuller, Smith & Turner P.L.C. (“Fuller’s” or “the Company”), the premium pubs and hotels business, today provides…
Halma plc Trading update Halma, the global group of life-saving technology companies focused on growing a safer, cleaner, healthier future for everyone, every day,…
ALLIANZ TECHNOLOGY TRUST PLC LEI: 549300OMDPMJU23SSH75 FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024 Highlights: Chairman’s Statement Welcome Welcome to this report on…